Lonza secures exclusive license to use Qurient CDK7 inhibitors for dual-payload ADCs

(AWP Alliance News) - Lonza entered an exclusive license agreement with South Korea's Qurient to use Qurient's CDK7 inhibitors in dual-payload antibody-drug conjugates, expanding its proprietary ADC technology platform. The deal adds a clinical-stage CDK7 inhibitor payload that can be paired with other payloads using Lonza's dual-payload technology.

The first product from the collaboration, SYN-duo(R) CC, combines exatecan with Qurient's CDK7 inhibitor as an off-the-shelf linker-payload for dual-payload ADC development. Lonza will also be able to develop additional dual-payload combinations using Qurient's CDK7 inhibitor under the agreement.

https://www.publicnow.com/view/3E61BEE7BFA23205B6E2A112BD4F941795B115E0…

Disclaimer: This news brief was created using generative artificial intelligence. Lonza Group Ltd. published the original content used to generate this news brief via EQS News on October 12, 2026, and is solely responsible for the information contained therein.